HighTower Advisors
IMNM icon

HighTower Advisors’s Immunome IMNM Stock Holding History

HighTower Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Sell
9,403
-1,628
-15% -$36.2K ﹤0.01% 3460
2025
Q4 		$237K Sell
11,031
-1,501
-12% -$26.3K ﹤0.01% 3224
2025
Q3 		$147K Sell
12,532
-126
-1% -$1.25K ﹤0.01% 3461
2025
Q2 		$118K Buy
+12,658
New +$104K ﹤0.01% 3436
2024
Q1 		– Sell
-16,818
Closed -$180K – 3816
2023
Q4 		$180K Sell
16,818
-2,000
-11% -$16.6K ﹤0.01% 3046
2023
Q3 		$157K Buy
18,818
+3,000
+19% +$22K ﹤0.01% 2997
2023
Q2 		$126K Sell
15,818
-1,000
-6% -$5.47K ﹤0.01% 3024
2023
Q1 		$83K Buy
+16,818
New +$82.3K ﹤0.01% 2977

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

HighTower Advisors's IMNM Position: Q1 2026 in Review

HighTower Advisors reduced its Immunome (IMNM) stake by 15% in Q1 2026, selling an estimated $36.2K and leaving 9,403 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

HighTower Advisors first reported a position in IMNM in Q1 2023 and has held it in 8 quarters since. The position peaked at $237K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • HighTower Advisors held 9,403 shares of Immunome worth $206K as of Q1 2026.
  • HighTower Advisors sold 1,628 Immunome shares in Q1 2026, an estimated $36.2K.
  • Immunome made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3460 holding.
  • HighTower Advisors first reported a position in Immunome in Q1 2023 and has held it in 8 quarters since.
  • HighTower Advisors's Immunome position peaked at $237K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.